| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种变应原及其致敏组分 | CN201510641179.3 | 2015-10-08 | CN106566822A | 2017-04-19 | 翁晖 |
| 本发明公开了一种变应原及其致敏组分，包括以下步骤，将患者在通常情况下接触的粉尘螨、美洲大蠊、印度谷斑螟及意大利蜜蜂四种变应原进行标准化饲养，将变应原提炼制成粗提液。本发明按变应原各致敏蛋白组分提取，按比例，研制成WHO所认可的标准化诊断及脱敏制剂，用于广大过敏性疾患的特异性免疫治疗，确保了变应原制剂的组成及疗效最佳，人群诊断的阳性率高，治疗的针对性强，将惠及广大过敏性疾患的身心健康。 | ||||||
| 2 | 包含脯氨酸特异性蛋白酶的食物产品 | CN200780004484.5 | 2007-01-30 | CN101511211A | 2009-08-19 | 路泊·埃登斯; 埃米尔·德德克 |
| 本发明涉及经巴氏灭菌的食物产品，其具有至少0.80的水分活度，优选至少0.85，并且包含脯氨酸特异性蛋白酶。 | ||||||
| 3 | DPP-4抑制剂 | CN201280054376.X | 2012-11-02 | CN103987724A | 2014-08-13 | 林田治; 楠畑雅; 厚沢雄二; 多贺祐喜; 小山洋一; 服部俊治 |
| 本发明提供一种DPP-4抑制剂，该DPP-4抑制剂以式(1)：Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd(式中，Xe表示等电点为5.9～6.3的氨基酸残基，Pro/Ala/Hyp表示Pro、Ala或Hyp，Xa表示Hyp、Pro和Arg以外的氨基酸残基或缺失，Xb表示Gly、Pro或缺失，Xc表示Pro、Ala或缺失，Xd表示氨基酸残基或缺失。)所示的肽作为有效成分。该抑制剂通过增强肠促胰岛素的作用，可以期待降低血糖值的作用，可以用作糖尿病治疗药，此外，通过对免疫系统等发挥作用，可用于皮肤疾病的治疗等。 | ||||||
| 4 | 含有蛋白酶的药物组合物和治疗溶酶体贮积病的方法 | CN201280028579.1 | 2012-06-08 | CN103796672A | 2014-05-14 | S·F·奥姆斯特德 |
| 本发明提供了一种治疗患有溶酶体贮积病例如戈谢病的受试者的方法和组合物，所述方法是通过给予患有溶酶体贮积病的受试者治疗有效量的组合物，所述组合物以足以改良、减少或改善所述疾病的至少一种症状的量包含至少一种蛋白酶或肽酶。本发明还提供了用于患有溶酶体贮积病的受试者的膳食补充剂。 | ||||||
| 5 | 新規な抗線維芽細胞活性化タンパク質(FAP)結合薬剤およびその使用 | JP2017132012 | 2017-07-05 | JP2018035137A | 2018-03-08 | ブロコップ,チャド; グリム,ヤン; コンバルジアー,ベノイト; ゲルスバッハ,マニュエル トビアス |
| 【課題】線維芽細胞活性化タンパク質(FAP)に伴う疾患の抗体に基づく治療および診断方法の提供。 【解決手段】抗体の相補性決定領域(CDR)ならびに/あるいは可変重鎖(VH)および/または可変軽鎖(VL)の少なくとも1つが、抗FAP抗体を産生したヒトメモリーB細胞から得られるmRNAに由来するcDNAによってコードされ、好ましくは、捕捉された、または直接に被覆されたヒトFAPに0.1μM以下のEC50で結合することができる、ヒトB細胞由来の抗線維芽細胞活性化タンパク質(FAP)モノクローナル抗体。 【選択図】なし |
||||||
| 6 | ジペプチジルペプチダーゼ−4阻害剤 | JP2011525782 | 2010-08-03 | JP5916387B2 | 2016-05-11 | 富永 雄仁; 横田 真一; 田中 穂積; 岸田 秀之; 北川 雅康; 舘 博; 太田 徹 |
| 7 | Method of treatment pharmaceutical compositions and lysosomal storage diseases containing a protease | JP2014514898 | 2012-06-08 | JP2014517015A | 2014-07-17 | スティーブン エフ オルムステッド |
| 【解決手段】本発明は、リソソーム蓄積症患者に、プロテアーゼまたはペプチダーゼの少なくとも1つを、該疾患の少なくとも1つの症状を向上、低減または改善するための充分量を含む組成物の治療的有効量を投与することによる、ゴーシェ病等のリソソーム蓄積症患者を治療するための方法および組成物を提供する。 また、本発明は、リソソーム蓄積症患者のための栄養補助食品を提供する。 | ||||||
| 8 | ジペプチジルペプチダーゼ−４阻害剤 | JP2011525782 | 2010-08-03 | JPWO2011016220A1 | 2013-01-10 | 雄仁 富永; 真一 横田; 田中 穂積; 穂積 田中; 岸田 秀之; 秀之 岸田; 雅康 北川; 博 舘; 太田 徹; 徹 太田 |
| 本発明は、食品を原料として得られる、味、吸収性の点からも経口摂取用途に適した、DPP−4阻害剤および該DPP−4阻害剤を含有する糖尿病を予防及び/又は改善する組成物を提供することを課題とする。本発明は、小豆またはインゲン豆を、微生物、または、微生物が産生する蛋白質分解酵素で処理して得られることを特徴とするDPP−4阻害剤を提供する。中でも小豆を麹または麹菌由来の蛋白質加水分解酵素で加水分解して、小豆中の蛋白質を断片化することにより、好適なDPP−4阻害剤が得られる。 | ||||||
| 9 | HUMANIZED DIPEPTIDYL PEPTIDASE IV (DPP4) ANIMALS | EP15727832.6 | 2015-05-28 | EP2993977B1 | 2018-07-18 | KYRATSOUS, Christos; MUJICA, Alexander |
| Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4 -encoding sequence with human DPP4 -encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described. | ||||||
| 10 | TETRAVALENT MULTISPECIFIC ANTIBODIES | EP15188057.2 | 2015-10-02 | EP3150636A1 | 2017-04-05 | The designation of the inventor has not yet been filed |
The present disclosure relates to novel tetravalent multispecific antibodies, their manufacture and use. |
||||||
| 11 | EPITOPE VACCINE FOR LOW IMMUNOGENIC PROTEIN AND PREPARING METHOD AND USAGE THEREOF | EP14797306 | 2014-05-14 | EP2998322A4 | 2016-12-14 | LI RONGXIU; ZHANG LI; ZHONG CONGHAO; CHENG CHAO; XU AIZHANG; LU WUGUANG; LIN ZHIBING |
| The present invention provides recombinant protein carrying an epitope. The recombinant protein has a skeleton structure from carrier protein, and a low immunogenic protein epitope is imported through splicing, replacement, and/or insertion to at least one molecular surface amino acid residue area of the carrier protein. The carrier protein has at least one T cell epitope, and the recombinant protein can effectively excite immunoreaction of an organism to the low immunogenic protein epitope. | ||||||
| 12 | PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEASES AND METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | EP12796468 | 2012-06-08 | EP2776059A4 | 2015-06-24 | OLMSTEAD STEPHEN F |
| The invention provides a method and compositions for treating a subject with a lysosomal storage disease such as gaucher disease, by administering to a subject with a lysosomal storage disease a therapeutically effective amount of composition comprising at least one of a protease or peptidase in an amount sufficient to ameliorate, reduce or improve at least one symptom of the disease. The invention also provides dietary supplements for subjects having lysosomal storage diseases. | ||||||
| 13 | COMPOSITIONS AND METHODS FOR REGULATING NEUTROPHIL MOVEMENT AND NEUTROPHIL NUMBERS IN A BODY REGION | EP12823790.6 | 2012-08-10 | EP2741764A2 | 2014-06-18 | GOMER, Richard; PHILLIPS, Jonathan; HERLIHY, Sarah; MAHARJAN, Anu; PILLING, Darrell |
| The disclosure includes compositions including dipeptidyl peptidase-IV (DPPIV) as well as compositions including an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium autocrine proliferation repressor A (AprA) region. The disclosure includes a method of reducing the number of neutrophils in a body region by administering a DPPIV composition to the body region in an amount and for a time sufficient to suppress neutrophil movement into the body region or enhancing neutrophil movement out of the body region. In particular, it relates to a method of reducing the number of neutrophils in a body region suffering from an acute injury or from a chronic or long-term disease. Further, the disclosure includes a method of increasing the number of neutrophils in a body region by administering an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium AprA region. | ||||||
| 14 | Enzyme treatment of foodstuffs for celiac sprue | EP11153783.3 | 2003-02-14 | EP2364718A1 | 2011-09-14 | Hausch, Felix; Gray, Gary; Shan, Lu; Khosla, Chaitan |
Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
|
||||||
| 15 | NOVEL DIPEPTIDYL PEPTIDASE (DP-IV) COMPOUNDS | EP09812753.3 | 2009-09-11 | EP2343973A1 | 2011-07-20 | KHAMAR, Bakulesh Mafatlal; CHANDAN, Singh; MODI, Rajiv, Indravadan |
| The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. wherein, A is defined as R 3-R 4 wherein R 3 and R 4 are together or independently defined as peptides having amino acids ranging from 1 to 10, B is chemical bond between peptide and substituted amine, R 1, and R 2 are as defined in specification, | ||||||
| 16 | Enzyme Formulation for Reducing Histamine Intolerance | US15853771 | 2017-12-23 | US20180117130A1 | 2018-05-03 | Thea Fournier |
| Disclosed is a formulation of the following enzymes: Alpha-galactosidase, Alpha amylase, Beta Glucanase, Lactase, BioCor DPP=IV (Proprietary blend) and Pectinase, which has been found to be effective in treating histamine intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: inflammation, pruritus, urticaria, hypotension, tachycardia, fatigue, migraines, conjunctivitis, incontinence, nasal congestion, panic attacks, acid reflux, depression and angioedema. | ||||||
| 17 | Enzyme formulation for reducing histamine intolerance | US15079404 | 2016-03-24 | US09849164B2 | 2017-12-26 | Thea Fournier |
| Disclosed is a formulation of the following enzymes: Alpha-galactosidase, Alpha amylase, Beta Glucanase, Lactase, BioCor DPP=IV (Proprietary blend) and Pectinase, which has been found to be effective in treating histamine intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: inflammation, pruritus, urticaria, hypotension, tachycardia, fatigue, migraines, conjunctivitis, incontinence, nasal congestion, panic attacks, acid reflux, depression and angioedema. | ||||||
| 18 | Enzyme Formulation for Reducing Histamine Intolerance | US15079404 | 2016-03-24 | US20170274056A1 | 2017-09-28 | Thea Fournier |
| Disclosed is a formulation of the following enzymes: Alpha-galactosidase, Alpha amylase, Beta Glucanase, Lactase, BioCor DPP=IV (Proprietary blend) and Pectinase, which has been found to be effective in treating histamine intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: inflammation, pruritus, urticaria, hypotension, tachycardia, fatigue, migraines, conjunctivitis, incontinence, nasal congestion, panic attacks, acid reflux, depression and angioedema. | ||||||
| 19 | Methods for treating cancer by administration of nucleic acids encoding FAP and cancer antigens | US15190794 | 2016-06-23 | US09744224B2 | 2017-08-29 | Hildegund C. J. Ertl; Ying Zhang |
| A immunogenic composition is provided for use in methods for treating or preventing the development of a cancer, comprising a nucleic acid sequence encoding a cancer antigen and a nucleic acid sequence encoding fibroblast activation protein (FAP). In one embodiment, the composition comprises a vector comprising a first expression cassette comprising a nucleic acid sequence encoding an antigen of a, operatively linked to an expression control sequence that directs the expression of the antigen in a mammalian host cell. The composition further contains a vector comprising a second expression cassette comprising a nucleic acid sequence encoding fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell. In one embodiment, the cancer is one in which tumor progression depends on the fibroblasts expressing fibroblast activation protein (FAP). | ||||||
| 20 | TETRAVALENT MULTISPECIFIC ANTIBODIES | US15281544 | 2016-09-30 | US20170145116A1 | 2017-05-25 | JOERG THOMAS REGULA; STEFAN SEEBER; WOLFGANG SCHAEFER; SABINE IMHOF-JUNG; MICHAEL MOLHOJ; MAXIMILIANE KOENIG; PETER BRUENKER; CHRISTIAN KLEIN |
| The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use. | ||||||
QQ群二维码
意见反馈
意见反馈